Trial Profile

Phase III trial of DaxibotulinumtoxinA for Upper Limb Spasticity

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daxibotulinumtoxin A (Primary)
Indications Muscle spasticity
Focus Registrational; Therapeutic Use
Sponsors Revance Therapeutics

Most Recent Events

10 May 2021 According to a Revance Therapeutics media release, End-of-Phase 2 meeting with the FDA anticipated in the second half of 2021 for DaxibotulinumtoxinA for Injection for the treatment of adults with upper limb spasticity.
22 Feb 2021 According to a Revance Therapeutics, the company plan to schedule an end-of-Phase 2 meeting with the FDA prior to finalizing a Phase 3 program.
03 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com